P/B
0,5
Standard BioTools
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
$266.4M
Market Cap • 10/7/2026
1999
(27 years)
Founded
2011
(15 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
3,1
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
3,1
BVPS
1,4
EPS
0,2
Market Cap
Market Cap
266,4M
EV
-182,2M
EV/Revenue
-2,2
EV/EBITDA
2
EV/EBIT
1,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,1%
Total Yield
-0,1%
Payout
0%
Retained Earnings
-1,2B
Profitability
Gross Margin
50,5%
EBITDA Margin
—
EBIT Margin
—
Net Margin
100,4%
D&A/EBITDA
0%
R&D/Revenue
21,8%
Capex/Revenue
2,7%
Capex/D&A
41,4%
Capex/OCF
-2,8%
SBC/OCF
—
% PPE
6,3%
% Goodwill
0%
ROE
17,6%
ROIC
—
Growth
CAGR Revenue 5Y
-10,6%
CAGR Op. Income 5Y
10,1%
CAGR OCF 5Y
17,5%
Leverage
N.D./EBITDA
5
Debt/Equity
0%
Current Ratio
9,1
Quick Ratio
8,4
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!